The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 results of selinexor in advanced de-differentiated (DDLS) liposarcoma (SEAL) study: A phase 2/3, randomized, double blind, placebo controlled cross-over study.
 
Mrinal M. Gounder
Honoraria - Amgen; Daiichi Sankyo; Epizyme; Karyopharm Therapeutics; TRACON Pharma
Consulting or Advisory Role - Amgen; Daiichi Sankyo; Epizyme; Karyopharm Therapeutics
Speakers' Bureau - Amgen
Travel, Accommodations, Expenses - Amgen; Daiichi Sankyo; Epizyme; Karyopharm Therapeutics
Other Relationship - Desmoid Tumor Research Foundation
 
Neeta Somaiah
Consulting or Advisory Role - Bayer; Deciphera; Immune Design
Research Funding - MedImmune
 
Steven Attia
Research Funding - AB Science (Inst); Bayer (Inst); Bayer (Inst); CytRx Corporation (Inst); Daiichi Sankyo (Inst); Dicephera Pharmaceuticals, Inc. (Inst); Epizyme (Inst); Immune Design (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Novartis (Inst); Novartis (Inst); TRACON Pharma (Inst)
Travel, Accommodations, Expenses - Immune Design
 
Sant P. Chawla
Honoraria - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Consulting or Advisory Role - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Speakers' Bureau - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Research Funding - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
 
Victor Manuel Villalobos
Consulting or Advisory Role - Abbvie; Ignyta; Janssen; Lilly; Novartis
Travel, Accommodations, Expenses - Janssen; Lilly; Xencor
 
Bartosz Chmielowski
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Eisai; Genentech/Roche; Immunocore; Merck
Speakers' Bureau - Genentech/Roche; Janssen Oncology
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech/Roche; Janssen; Merck
 
Melissa Amber Burgess
Consulting or Advisory Role - EMD Serono
Travel, Accommodations, Expenses - Lilly
 
Gary K. Schwartz
Honoraria - BioMotiv; Bionaut Labs; Champions Oncology; Daiichi Sankyo; DarwinHealth; Human Longevity, Inc; Karyopharm Therapeutics
Consulting or Advisory Role - BioMotiv; Bionaut Labs; Champions Oncology; Daiichi Sankyo; DarwinHealth; Human Longevity, Inc; Karyopharm Therapeutics; PureTech
Research Funding - Astex Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Patent pending regarding development of PNAs for targeted cancer therapy (new technology)
Travel, Accommodations, Expenses - Daiichi Sankyo
 
Richard F. Riedel
Employment - Biotech Prosthetic Orthotics of North Carolina (I); Limbguard (I)
Leadership - Biotech Prosthetic Orthotics of North Carolina (I); Limbguard (I)
Stock and Other Ownership Interests - Biotech Prosthetic Orthotics of North Carolina (I); Limbguard (I)
Consulting or Advisory Role - Daiichi Sankyo; Eisai; GlaxoSmithKline; Ignyta; Lilly; Loxo; Merck; Novartis
Research Funding - AADi (Inst); Agios (Inst); Arog (Inst); Astex Pharmaceuticals (Inst); Bayer (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Ignyta (Inst); Immune Design (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Plexxikon (Inst); Threshold Pharmaceuticals (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - PandoNet - Limbguard (I)
Travel, Accommodations, Expenses - Daiichi Sankyo; EMD Serono; Ignyta; Janssen
 
Margaret von Mehren
Consulting or Advisory Role - Blueprint Medicines; CytRx Corporation; deciphera; Janssen Oncology
Research Funding - ArQule
Travel, Accommodations, Expenses - Arog
Other Relationship - NCCN
 
Andrew J. Wagner
Consulting or Advisory Role - Five Prime Therapeutics; Lilly; Loxo
Research Funding - AADi (Inst); Celldex (Inst); Daiichi Sankyo (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Plexxikon (Inst)
 
Edwin Choy
Consulting or Advisory Role - Bayer; EMD Serono; Immune Design; NPS Pharmaceuticals; Pfizer
Research Funding - Amgen (Inst); AstraZeneca (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bayer; EMD Serono; NPS Pharmaceuticals
 
Shailendra Verma
No Relationships to Disclose
 
Boyd Mudenda
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Mara Sadanowicz
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Jatin J. Shah
Employment - Karyopharm Therapeutics
Leadership - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Lingling Li
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Sharon Shacham
Employment - Karyopharm Therapeutics
Leadership - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Michael G. Kauffman
Employment - Karyopharm Therapeutics
Leadership - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Albiruni Ryan Abdul Razak
Honoraria - Boehringer Ingelheim
Consulting or Advisory Role - Boehringer Ingelheim; Lilly; Merck
Research Funding - Amgen; Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; CASI Pharmaceuticals; Deciphera; Karyopharm Therapeutics; Lilly; MedImmune; Novartis; Pfizer; Roche/Genentech